These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 37165798)
1. Novel ester tethered dihydroartemisinin-3-(oxime/thiosemicarbazide)isatin hybrids as potential anti-breast cancer agents: Synthesis, in vitro cytotoxicity and structure-activity relationship. Liu S; Wang S; Xu D; Pan B; Chen L; Zhao S; Xu Z; Zhou W Drug Dev Res; 2023 Sep; 84(6):1175-1182. PubMed ID: 37165798 [TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of Novel Amyl Ester Tethered Dihydroartemisinin-Isatin Hybrids as Potent Anti-Breast Cancer Agents. Xu Z; Zhang X; Liu J; Zhao S; Liu J; Zhou W Chem Biodivers; 2023 Mar; 20(3):e202201257. PubMed ID: 36808231 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and in vitro cytotoxicity evaluation of novel dihydroartemisinin-isatin hybrids tethered via different length of esters as potential anti-breast cancer agents. Xu Z; Pan B; Chen L; Xu D Fitoterapia; 2023 Apr; 166():105436. PubMed ID: 36693438 [TBL] [Abstract][Full Text] [Related]
4. The anti-breast cancer potential of dihydroartemisinin-isatin hybrids with hydrogen bond donors at C-3 position of isatin moiety. Ding F; Chen X; Cao W; Dong T; Wang P Fitoterapia; 2023 Mar; 165():105426. PubMed ID: 36608710 [TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and anti-breast cancer properties of butyric ester tethered dihydroartemisinin-isatin hybrids. Zhao S; Zhang X; Tang M; Liu X; Deng J; Zhou W; Xu Z Med Chem Res; 2023; 32(4):705-712. PubMed ID: 36816432 [TBL] [Abstract][Full Text] [Related]
6. The Anti-Breast Cancer Potential of Bis-Isatin Scaffolds. Guo H; Diao QP Curr Top Med Chem; 2020; 20(16):1499-1503. PubMed ID: 32156238 [TBL] [Abstract][Full Text] [Related]
7. The Anti-Breast Cancer Activity of Dihydroartemisinin-5-methylisatin Hybrids Tethered via Different Carbon Spacers. Yao Y; Wang H; Xu J; Gao F; Cao W Molecules; 2022 Nov; 27(22):. PubMed ID: 36432095 [TBL] [Abstract][Full Text] [Related]
8. Synthesis of 1H-1,2,3-Triazole-Linked Quinoline-Isatin Molecular Hybrids as Anti-Breast Cancer and Anti-Methicillin-Resistant Staphylococcus aureus (MRSA) Agents. Awolade P; Cele N; Ebenezer O; Kerru N; Gummidi L; Gu L; Palma G; Kaur M; Singh P Anticancer Agents Med Chem; 2021; 21(10):1228-1239. PubMed ID: 32990543 [TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities. Yang M; Liu H; Zhang Y; Wang X; Xu Z Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464 [TBL] [Abstract][Full Text] [Related]
10. Artemisinin-isatin hybrids tethered via ethylene linker and their anti-lung cancer activity. Wang R; Zhang Q; Chen M Arch Pharm (Weinheim); 2023 Apr; 356(4):e2200563. PubMed ID: 36572639 [TBL] [Abstract][Full Text] [Related]
11. Two-carbon tethered artemisinin-isatin hybrids: design, synthesis, anti-breast cancer potential, and Wang R; Huang R; Yuan Y; Wang Z; Shen K Front Mol Biosci; 2023; 10():1293763. PubMed ID: 37928644 [TBL] [Abstract][Full Text] [Related]
12. Novel Thiazolidinone/Thiazolo[3,2- El-Naggar M; Eldehna WM; Almahli H; Elgez A; Fares M; Elaasser MM; Abdel-Aziz HA Molecules; 2018 Jun; 23(6):. PubMed ID: 29895744 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of novel morpholinated isatin-quinoline hybrids as potent anti-breast cancer agents. Singh A; Kaur H; Arora S; Bedi PMS Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100368. PubMed ID: 34783073 [TBL] [Abstract][Full Text] [Related]
14. In-vitro Evaluation of Isatin Derivatives as Potent Anti-Breast Cancer Agents against MCF-7, MDA MB 231, MDA-MB 435 and MDA-MB 468 Breast Cancers Cell Lines: A Review. Chauhan G; Pathak DP; Ali F; Dubey P; Khasimbi S Anticancer Agents Med Chem; 2022; 22(10):1883-1896. PubMed ID: 34477529 [TBL] [Abstract][Full Text] [Related]
15. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents. Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751 [TBL] [Abstract][Full Text] [Related]
16. Triazole tethered isatin-coumarin based molecular hybrids as novel antitubulin agents: Design, synthesis, biological investigation and docking studies. Singh H; Singh JV; Gupta MK; Saxena AK; Sharma S; Nepali K; Bedi PMS Bioorg Med Chem Lett; 2017 Sep; 27(17):3974-3979. PubMed ID: 28797799 [TBL] [Abstract][Full Text] [Related]
17. Synthesis, anticancer evaluation and pharmacokinetic study of novel 10-O-phenyl ethers of dihydroartemisinin. Luan S; Zhong H; Zhao X; Yang J; Jing Y; Liu D; Zhao L Eur J Med Chem; 2017 Dec; 141():584-595. PubMed ID: 29102180 [TBL] [Abstract][Full Text] [Related]
18. Synthesis of novel 1H-1,2,3-triazole tethered C-5 substituted uracil-isatin conjugates and their cytotoxic evaluation. Kumar K; Sagar S; Esau L; Kaur M; Kumar V Eur J Med Chem; 2012 Dec; 58():153-9. PubMed ID: 23124212 [TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and QSAR study of certain isatin-pyridine hybrids as potential anti-proliferative agents. Eldehna WM; Altoukhy A; Mahrous H; Abdel-Aziz HA Eur J Med Chem; 2015 Jan; 90():684-94. PubMed ID: 25499988 [TBL] [Abstract][Full Text] [Related]